Peripheral Neuropathy Induced by Subcutaneous Bortezomib-Based Induction Therapy for Newly Diagnosed Multiple Myeloma

Haematologica - Italy
doi 10.3324/haematol.2014.110221
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Changes in Uninvolved Immunoglobulins During Induction Therapy for Newly Diagnosed Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2017English

Impact of Concomitant Dexamethasone Dosing Schedule on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma

British Journal of Haematology
Hematology
2017English

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Stem Cells International
Cell BiologyMolecular Biology
2012English

Bortezomib-Based Regimens Used as Induction in Newly Diagnosed Multiple Myeloma (Ndmm) Patients Eligible for Stem Cell Transplantation (Sct)The Cost-Utility Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Bortezomib-Based Consolidation or Maintenance Therapy for Multiple Myeloma: A Meta-Analysis

Blood Cancer Journal
OncologyHematology
2020English

A Dose Increased Once-Weekly Bortezomib-Based Combination Therapy for Multiple Myeloma

Oncotarget
Oncology
2016English

Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates

Cancer Journal
Cancer ResearchOncology
2009English

The Impact of ASCT on Patients With Newly Diagnosed Multiple Myeloma Who Receive RVD Induction

Journal of Hematological Malignancies
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy